Corvus Pharmaceuticals, Inc. (CRVS) Balance Sheet

The balance sheet shows a massive equity infusion in 2026, likely from a financing event, but the underlying trend is deteriorating: accumulated deficit grew from -$340.4M to -$443.9M over ten quarters. This suggests that while the company has temporarily bolstered its equity base, it continues to burn through capital at an accelerating pace, with quarterly losses widening from $6.3M to $19.3M. The reliance on external financing rather than operational progress signals a weakening balance sheet trajectory.

The current ratio appears robust, but it is inflated by the recent equity raise; the quick ratio, excluding inventory, would be similar given minimal receivables. However, with quarterly operating losses now exceeding $19M, the $18.9M cash balance provides less than one quarter of runway. This suggests that without additional financing or a significant reduction in burn, the company faces imminent liquidity constraints, consistent with the prior cash flow analysis indicating a deteriorating cash position.

The balance sheet shows negligible debt, which might suggest low financial risk, but this is misleading for a clinical-stage biotech. The company has no revenue and must fund operations through equity issuance, leading to significant dilution for existing shareholders. The low debt levels do not mitigate the risk of future dilutive offerings, especially given the cash burn rate. Investors should monitor the pace of cash consumption relative to the ability to raise capital on favorable terms.

The asset base is almost entirely composed of cash and short-term investments, with negligible property, plant, and equipment. This indicates that the company's value lies in its intellectual property and clinical pipeline, which are not capitalized on the balance sheet. The absence of goodwill and intangibles suggests no acquisition-related impairments, but it also means the balance sheet provides little cushion against operational losses. The minimal PPE underscores that the company's expenditures are directed toward R&D rather than fixed assets.

The equity account is dominated by paid-in capital from recent financing activities, not by retained earnings, which are deeply negative. This suggests that the company has not generated any internal equity growth and is entirely dependent on investor funding. The large equity balance may provide a temporary buffer, but the persistent negative retained earnings highlight the lack of profitability. Stock-based compensation, which added $2.6M in 2026Q2, further dilutes existing shareholders and may mask the true economic cost of operations.